Pulmonary Arterial Hypertension in Systemic Sclerosis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00617487
Recruitment Status :
Active, not recruiting
First Posted : February 18, 2008
Last Update Posted : March 7, 2018
IRCCS Policlinico S. Matteo
Information provided by (Responsible Party):
Carlomaurizio Montecucco, IRCCS Policlinico S. Matteo
The purpose of this study is to evaluate the role of stress echocardiography, compared to standard echocardiography in the early identification of pulmonary arterial hypertension in systemic sclerosis. To evaluate the role of BNP in this setting.To analyze data recorded with respect to the parameters commonly used for SSc evaluation (eg thorax HRCT, pulmonary function tests + DLCO, nailfold capillaroscopy, etc); these parameters are available starting for 1999.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 90 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
patients with systemic sclerosis
Patients with systemic sclerosis according to LeRoy criteria
Significant valvular disease
Low left ventricular function upon echocardiography (ejection fraction<55%)
History of atrial fibrillation, myocardial infarction, pulmonary thromboembolisms, neoplasia or severe hepatic disease.